XML 49 R38.htm IDEA: XBRL DOCUMENT v3.20.2
Related Party Transactions - Additional Information (Details)
12 Months Ended
Dec. 17, 2019
USD ($)
shares
Dec. 16, 2019
USD ($)
shares
Nov. 01, 2019
Jun. 30, 2020
USD ($)
shares
Jun. 30, 2019
USD ($)
shares
Jun. 30, 2018
USD ($)
shares
Mar. 21, 2018
USD ($)
Nov. 13, 2017
USD ($)
Related Party Transaction [Line Items]                
Other General and Administrative Expense       $ 2,000        
Percentage of Direct Costs       30.00%        
Percentage Of Net Sales Allocated For Royalty Payments       15.00%        
Research and Development Expense       $ 4,695,524 $ 5,921,720 $ 5,913,720    
Series A shares issued in exchange of deferred development fees owed (in shares) | shares       100,000        
Accrued Royalties       $ 0 0 0    
Deferred development fees exchanged for shares       250,000        
Loss on exchange of shares       142,669        
Debenture paid             $ 4,730,000 $ 4,730,000
Coupon interest expense       93,670 0 185,274    
Series C Convertible Debenture [Member]                
Related Party Transaction [Line Items]                
Debenture paid       5,000,000       $ 5,000,000
Coupon interest expense       0 0 185,274    
TheraCour                
Related Party Transaction [Line Items]                
Percentage Of Net Sales Allocated For Royalty Payments     15.00%          
TheraCour                
Related Party Transaction [Line Items]                
Research and Development Expense       2,158,034 $ 3,119,863 $ 3,176,977    
Series A Preferred stock                
Related Party Transaction [Line Items]                
Stock Issued During Period, Shares, Share-based Compensation, Gross | shares   10,000     29,138 2,888    
Stock Issued During Period, Value, Share-based Compensation, Gross   $ 39,301   392,669 $ 609,518 $ 136,106    
Converted value to common shares   3.50            
Amortization expense on loan origination fee       $ 21,288        
Series A Preferred stock | TheraCour                
Related Party Transaction [Line Items]                
Deferred monthly development fees $ 25,000              
Series A shares issued in exchange of deferred development fees owed (in shares) | shares 100,000              
Stock Issued During Period, Value, Share-based Compensation, Gross $ 392,669              
Deferred development fees exchanged for shares 250,000              
Loss on exchange of shares $ 142,669